Valneva (VALN) Competitors $10.18 +0.23 (+2.31%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$10.24 +0.05 (+0.54%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. SRRK, RARE, CNTA, MOR, IMVT, XENE, VKTX, OGN, KNSA, and NAMSShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), Centessa Pharmaceuticals (CNTA), MorphoSys (MOR), Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors Scholar Rock Ultragenyx Pharmaceutical Centessa Pharmaceuticals MorphoSys Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Scholar Rock (NASDAQ:SRRK) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Which has more risk & volatility, SRRK or VALN? Scholar Rock has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Do analysts rate SRRK or VALN? Scholar Rock currently has a consensus target price of $46.20, indicating a potential upside of 49.81%. Valneva has a consensus target price of $15.00, indicating a potential upside of 47.35%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities analysts clearly believe Scholar Rock is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23Valneva 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SRRK or VALN more profitable? Scholar Rock has a net margin of 0.00% compared to Valneva's net margin of -33.87%. Valneva's return on equity of -34.78% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -127.11% -90.09% Valneva -33.87%-34.78%-13.43% Which has higher valuation and earnings, SRRK or VALN? Valneva has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M89.32-$246.29M-$2.91-10.60Valneva$183.52M4.77-$13.25M-$0.98-10.39 Do insiders and institutionals have more ownership in SRRK or VALN? 91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor SRRK or VALN? In the previous week, Scholar Rock had 30 more articles in the media than Valneva. MarketBeat recorded 33 mentions for Scholar Rock and 3 mentions for Valneva. Scholar Rock's average media sentiment score of 0.73 beat Valneva's score of 0.29 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryScholar Rock beats Valneva on 9 of the 17 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$874.77M$10.61B$5.80B$10.46BDividend YieldN/A1.89%5.61%4.57%P/E Ratio-10.3921.7780.5726.86Price / Sales4.7732.05535.48125.22Price / Cash104.1925.0926.0131.15Price / Book4.223.4215.776.42Net Income-$13.25M$210.63M$3.30B$271.73M7 Day Performance14.00%0.78%3.93%2.82%1 Month Performance-12.54%-2.12%5.32%6.60%1 Year Performance73.13%-9.87%80.88%28.60% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.6288 of 5 stars$10.18+2.3%$15.00+47.3%+73.1%$874.77M$183.52M-10.39700SRRKScholar Rock4.3495 of 5 stars$33.67+6.3%$46.33+37.6%+228.4%$3.04BN/A-11.57140RAREUltragenyx Pharmaceutical4.3841 of 5 stars$29.00-4.3%$81.50+181.0%-52.1%$2.92B$560.23M-5.241,294Positive NewsCNTACentessa Pharmaceuticals3.2015 of 5 stars$22.02+1.0%$32.44+47.3%+37.5%$2.92B$6.85M-12.30200MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant2.2306 of 5 stars$15.53-3.9%$33.60+116.4%-49.4%$2.82BN/A-5.45120Positive NewsXENEXenon Pharmaceuticals2.3238 of 5 stars$35.99-0.6%$53.30+48.1%-8.0%$2.79B$7.50M-10.14210Positive NewsVKTXViking Therapeutics4.2592 of 5 stars$24.08-2.9%$87.50+263.4%-64.0%$2.79BN/A-15.7420OGNOrganon & Co.4.5743 of 5 stars$10.39-2.5%$17.33+66.9%-46.3%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.6666 of 5 stars$36.56-1.5%$41.17+12.6%+38.1%$2.75B$423.24M914.23220NAMSNewAmsterdam Pharma3.0977 of 5 stars$24.12-0.3%$41.55+72.2%+67.7%$2.72B$45.56M-14.894Positive News Related Companies and Tools Related Companies SRRK Alternatives RARE Alternatives CNTA Alternatives MOR Alternatives IMVT Alternatives XENE Alternatives VKTX Alternatives OGN Alternatives KNSA Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredThis soon could be the most precious company in AmericaAI is devouring power at an unprecedented rate. Google alone expects its annual electricity bill to jump by $2...True Market Insiders | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
